TherapeuticsMD TXMD Estimates

NASDAQ TXMD
$2.17 +0.03 (+1.40%)
As of: Sep 9, 2026 · 10:55 AM EDT
Analyst Estimates

TherapeuticsMD, Inc. Revenue Estimates

Periods 24
Next Period Q2 23
Consensus 522,175.00

Analysts expect TherapeuticsMD, Inc. to report revenue of 522,175.00 for Q2 23, against a range of 485,027.99 to 559,322.01. The most recent reported quarter, Q1 23, came in at 400,000.00, a 75.7% miss against the 1.65 M consensus.

Metric Q1 23Q2 23Q3 23Q4 23Q1 24Q2 24Q3 24Q4 24Q1 25Q2 25Q3 25Q4 25Q1 26Q2 26Q3 26Q4 26Q1 27Q2 27Q3 27Q4 27Q1 28Q2 28Q3 28Q4 28
Reported (Actual) 400,000.00--------
High Estimate 1.72 M559,322.01558,009.18591,099.672.21 M2.43 M2.28 M2.59 M2.74 M
Low Estimate 1.57 M485,027.99503,620.82535,406.332.03 M2.13 M2.04 M2.13 M2.41 M
Consensus Estimate 1.65 M522,175.00530,815.00563,253.002.12 M2.28 M2.16 M2.36 M2.57 M
Analyst Estimates

TherapeuticsMD, Inc. Earnings Per Share (EPS) Estimates

Periods 24
Next Period Q4 24
Consensus 0.04

Analysts expect TherapeuticsMD, Inc. to report earnings per share of 0.04 for Q4 24, against a range of 0.04 to 0.04. The most recent reported quarter, Q3 24, came in at -0.05, a 225.0% miss against the 0.04 consensus.

Metric Q1 23Q2 23Q3 23Q4 23Q1 24Q2 24Q3 24Q4 24Q1 25Q2 25Q3 25Q4 25Q1 26Q2 26Q3 26Q4 26Q1 27Q2 27Q3 27Q4 27Q1 28Q2 28Q3 28Q4 28
Reported (Actual) -0.24-0.24-0.13-0.13-0.07-0.09-0.05--------
High Estimate 0.06-0.06-0.15-0.120.030.030.040.040.040.000.020.100.070.010.02
Low Estimate 0.06-0.08-0.17-0.140.030.030.040.040.040.000.020.080.050.010.02
Consensus Estimate 0.06-0.07-0.16-0.130.030.030.040.040.040.000.020.090.060.010.02